DBV Technologies S.A.
DBVT · XNASCIK 1613780fmd_1TPGN78NJ578SBP3RNRSD6WB0KManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 32 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 11 | 6 | 5 | 16 | 4 | 6 |
| Research and development | 115 | 102 | 70 | 76 | 60 | 89 | 117 |
| Selling, general and administrative | 71 | 45 | 35 | 26 | 32 | 31 | 36 |
| Total operating expenses | 186 | 170 | 104 | 101 | 92 | 121 | 153 |
| Operating income | (171) | (159) | (99) | (97) | (76) | (117) | (147) |
| Income before taxes | (171) | (160) | (98) | (96) | (73) | (114) | (146) |
| Income tax expense | 1 | (0) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (172) | (160) | (98) | (96) | (73) | (114) | (147) |
| Net income | (172) | (160) | (98) | 96 | 73 | (114) | (147) |
| Net income to common shareholders | (172) | (160) | (98) | (96) | (73) | (114) | (147) |